Source: Virtual Congress 2021 – Treatments for airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bourdin (Montpellier Cedex 5, France), M. Maravic (Paris, France), L. Perray (Courbevoie, France), N. Roche (Paris, France). Impact of COVID-19 on treatments’ dispensations for chronic airways diseases in France. 1835

Member's Comments

No comment yet.

Related content which might interest you: Effect of different asthma treatments on risk of cold-related exacerbations Source: Eur Respir J 2011; 38: 584-593 Year: 2011 Drug use profiles before, during and after hospitalization for chronic obstructive pulmonary disease in the Netherlands Source: Eur Respir J 2004; 24: Suppl. 48, 84s Year: 2004 Current maintenance treatment of chronic obstructive pulmonary disease in China Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 The best papers in the ERJ: chronic airways diseases, including asthma and COPD Source: Virtual Congress 2020 – The European Respiratory Journal editor's view: our best papers of last year Year: 2020 Tele-rehabilitation in chronic lung diseases Source: ERS Course 2017 Year: 2017 Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema Source: Eur Respir J 2001; 17: 596-603 Year: 2001 Prevention of exacerbations of COPD with pharmacotherapy Source: Eur Respir Rev 2009; 19: 119-126 Year: 2010 Prioritised research agenda for prevention and control of chronic respiratory diseases Source: Eur Respir J 2010; 36: 995-1001 Year: 2010 The impact of acute exacerbations of chronic bronchitis on patients’ quality-of-life in Europe and USA Source: Eur Respir J 2004; 24: Suppl. 48, 410s Year: 2004 Adherence rate to inhaled therapies and factors affecting adherence in elderly with chronic obstructive lung diseases Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Impact of bacterial infections on airway diseases Source: Eur Respir Rev 2005; 14: 62-68 Year: 2005 Drug prescribing and burden of asthma and chronic obstructive pulmonary disease (COPD): a study from Italian general practitioners Source: Eur Respir J 2005; 26: Suppl. 49, 672s Year: 2005 Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Source: Eur Respir Rev 2006; 15: 47-51 Year: 2006 The threat in chronic lung diseases: acute exacerbations Source: Eur Respir Rev, 26 (145) 170075; 10.1183/16000617.0075-2017 Year: 2017 Poor adherence to ICS treatment in patients with chronic respiratory diseases Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 Prescription of opioids for breathlessness in end-stage chronic obstructive pulmonary disease: A national population based study Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases Year: 2016 Exacerbations and symptoms remain common in patients with asthma control: A survey of 8000 patients in Europe Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – COPD diagnosis and management Year: 2016 The prevalence of asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS) in a Northern Italy general population sample Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015